Gabapentin and Slynd drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gabapentin (gabapentin) and Slynd (drospirenone). Common drug interactions include apathy among females.

The phase IV clinical study analyzes what interactions people have when they take Gabapentin and Slynd. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Gabapentin?

Gabapentin has active ingredients of gabapentin. It is often used in peripheral neuropathy. eHealthMe is studying from 322,990 Gabapentin users. Check the latest studies of Gabapentin.

What is Slynd?

Slynd has active ingredients of drospirenone. It is often used in birth control. eHealthMe is studying from 1,658 Slynd users. Check the latest studies of Slynd.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

16 people who take Gabapentin and Slynd together, and have interactions are studied.

What are the common drug interactions of Gabapentin and Slynd, by gender? *:

female:

Apathy
Calcium deficiency (lack of calcium)
Alopecia (absence of hair from areas of the body)
Vitreous detachment (a condition of the eye in which the vitreous humour separates from the retina)
Drug ineffective
Fungal infection
Chronic kidney disease
Hypoaesthesia (reduced sense of touch or sensation)
Limb discomfort (discomfort in leg)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)

male:

n/a

What are the common drug interactions of Gabapentin and Slynd, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Diarrhoea
Drug hypersensitivity
Gastrointestinal hypomotility (less activity of the intestinal tract)
Hunger
Hyperhidrosis (abnormally increased sweating)
Stress
Urinary tract infection
Weight decreased
Alopecia (absence of hair from areas of the body)
Vitreous detachment (a condition of the eye in which the vitreous humour separates from the retina)

40-49:

Hypoaesthesia (reduced sense of touch or sensation)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Dysgeusia (disorder of the sense of taste)
Immunodeficiency
Injection site pruritus (severe itching at injection site)
Injection site reaction
Injection site swelling
Pneumonia

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 8 people, 50.00%
Drowsiness: 8 people, 50.00%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 8 people, 50.00%
Peristalsis Visible (visible wavelike muscular contractions of the alimentary canal or other tubular structures): 5 people, 31.25%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 1 person, 6.25%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 6.25%
Migraine (headache): 1 person, 6.25%
Menstrual Disorder (disease of menstrual cycle): 1 person, 6.25%
Intervertebral Disc Protrusion (spinal disc protrusion): 1 person, 6.25%
Friedreich's Ataxia (damage to the nervous system): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Gabapentin and Slynd?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously